focus -WSS

focus

author：focus 2025-09-06 03:41:05 Page View：1292

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The release of Novo Nordisk’s latest earnings report on Thursday provided a chance for executives to tout their major win this week — outcomes from a large trial showing the company’s obesity drug Wegovy cut the risk of heart complications by 20%.

But once again, much of the attention was focused on the company’s struggles to meet what Novo CEO Lars Fruergaard Jørgensen referred to as the “overwhelming demand for Wegovy.”

Jørgensen reiterated that the company was racing to expand supply and had brought on more contract manufacturing support, but Novo said Thursday that the company would continue to restrict the availability of lower-strength starter doses in the United States to ensure that patients on the drug would not have their medication interrupted.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Shkreli is convicted of fraud. Can pharma finally slam the door on him?
Next article： FDA approval of Sarepta Duchenne genetic therapy gives me hope

knowledge

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

How dance can help health care workers heal from trauma

“Youcan’tpourfromanemptycup”iswhatregisterednurseTaraRynderslearnedthehardwayaftertwodecadesofworkan

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

Stanford updates investigation of president’s past research

PeoplewalkonthecampusatStanfordUniversityinStanford,Calif.JeffChiu/APAninvestigationbyaspecialcommit

focus

Wikipedia

knowledge

Stanford updates investigation of president’s past research